Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's
(MedPage Today) -- Mirodenafil (known as AR1001), an oral phosphodiesterase-5 inhibitor approved in South Korea to treat erectile dysfunction, showed mixed results in people with early Alzheimer's disease in the phase III POLARIS-AD trial. The...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.